#BiFunctionalADCs - Twitter Hashtag

about 2 years ago

Leveraging our Delta receptor technology, we are developing first-in-class bi-functional antibody drug conjugates to target #MyeloidDerivedSuppressor Cells. Learn more about our approach here: https://t.co/kQSgup0qNB #BiFunctionalADCs #TumorMicroenvironment

TuhuraBio's tweet photo. Leveraging our Delta receptor technology, we are developing first-in-class bi-functional antibody drug conjugates to target #MyeloidDerivedSuppressor Cells. Learn more about our approach here: https://t.co/kQSgup0qNB

#BiFunctionalADCs #TumorMicroenvironment https://t.co/Md1Gsq4GTj

1

2

1

0

155

TuHURA

@TuhuraBio

about 2 years ago

We are leveraging cancer vaccines to to initiate an immune response to tumor neoantigens, which are the abnormal proteins that tumor-associated genetic mutations cause tumor cells to produce. Learn more: https://t.co/gY3iDAblIW #PersonalCancerVaccine #BiFunctionalADCs

TuhuraBio's tweet photo. We are leveraging cancer vaccines to to initiate an immune response to tumor neoantigens, which are the abnormal proteins that tumor-associated genetic mutations cause tumor cells to produce. Learn more: https://t.co/gY3iDAblIW

#PersonalCancerVaccine #BiFunctionalADCs https://t.co/1VEzVuQHk8

0

3

1

0

207

TuHURA

@TuhuraBio

about 2 years ago

We are a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. #PersonalCancerVaccine #BiFunctionalADCs #MerkelCell #SquamousCell

TuhuraBio's tweet photo. We are a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy.

#PersonalCancerVaccine #BiFunctionalADCs #MerkelCell #SquamousCell https://t.co/UouvcQv9A5

0

1

0

153

TuHURA

@TuhuraBio

about 2 years ago

Our #BiFunctionalADCs represent a new class of ADCs and a paradigm shift in this important therapeutic class of drugs. Learn more here: https://t.co/kQSgup0qNB #CancerVaccines #TumorMicroenviornment

TuhuraBio's tweet photo. Our #BiFunctionalADCs represent a new class of ADCs and a paradigm shift in this important therapeutic class of drugs.

Learn more here: https://t.co/kQSgup0qNB
#CancerVaccines #TumorMicroenviornment https://t.co/SSP5pgdL9g

0

4

2

0

2K

TuHURA

@TuhuraBio

over 2 years ago

We are developing novel technologies that are designed to overcome primary and acquired resistance to #checkpointinhibitors or cellular therapies in the treatment of cancer. https://t.co/rshry0yx6s #PersonalCancerVaccine #BiFunctionalADCs #MerkelCell #SquamousCell